JP2020503359A5 - - Google Patents
Info
- Publication number
- JP2020503359A5 JP2020503359A5 JP2019536507A JP2019536507A JP2020503359A5 JP 2020503359 A5 JP2020503359 A5 JP 2020503359A5 JP 2019536507 A JP2019536507 A JP 2019536507A JP 2019536507 A JP2019536507 A JP 2019536507A JP 2020503359 A5 JP2020503359 A5 JP 2020503359A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- nos
- netrin
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022151769A JP2022176250A (ja) | 2017-01-05 | 2022-09-22 | ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305014 | 2017-01-05 | ||
| EP17305014.7 | 2017-01-05 | ||
| PCT/EP2018/050289 WO2018127570A1 (en) | 2017-01-05 | 2018-01-05 | Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022151769A Division JP2022176250A (ja) | 2017-01-05 | 2022-09-22 | ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503359A JP2020503359A (ja) | 2020-01-30 |
| JP2020503359A5 true JP2020503359A5 (cg-RX-API-DMAC7.html) | 2022-05-20 |
| JP7211952B2 JP7211952B2 (ja) | 2023-01-24 |
Family
ID=57838304
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536507A Active JP7211952B2 (ja) | 2017-01-05 | 2018-01-05 | ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療 |
| JP2022151769A Pending JP2022176250A (ja) | 2017-01-05 | 2022-09-22 | ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022151769A Pending JP2022176250A (ja) | 2017-01-05 | 2022-09-22 | ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12162932B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3565837B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7211952B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102679324B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110291105B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018205730B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3048347A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA039433B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL267775B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018127570A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3565837B1 (en) | 2017-01-05 | 2024-04-10 | Netris Pharma | Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs |
| MX2024001308A (es) * | 2021-07-27 | 2024-05-23 | Netris Pharma | Deteccion de netrina-1, prueba complementaria y terapia basada en radiaciones. |
| CA3246346A1 (en) * | 2022-03-29 | 2023-10-05 | Netris Pharma | NEW MCL-1 INHIBITOR AND COMBINATION OF MCL-1 AND A BH3 MIMETIC, SUCH AS A BCL-2 INHIBITOR |
| WO2024095723A1 (ja) | 2022-11-02 | 2024-05-10 | シチズン・システムズ株式会社 | プリンタ |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| ES2601352T3 (es) | 2006-02-28 | 2017-02-14 | Centre National De La Recherche Scientifique (Cnrs) | Cribado para compuestos anti-cáncer usando actividad de netrina-1 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| EP2609430A1 (en) | 2010-08-26 | 2013-07-03 | F.Hoffmann-La Roche Ag | Recombinant fc-fusion protein of the fifth fibronectin type iii domain of dcc |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| EP2708231A1 (en) | 2012-09-12 | 2014-03-19 | Netris Pharma | Combined treatment with netrin-1 interfering drug and chemotherapeutic drug |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| EP2893939A1 (en) * | 2014-01-10 | 2015-07-15 | Netris Pharma | Anti-netrin-1 antibody |
| UA122479C2 (uk) * | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| CN104083762A (zh) * | 2014-06-27 | 2014-10-08 | 中国科学院生物物理研究所 | 用于阻断Netrin-1与CD146之间的相互作用的试剂及其肿瘤治疗用途 |
| NZ738406A (en) | 2015-06-11 | 2023-04-28 | Bionomics Ltd | Pharmaceutical combination of a tubulin polymerization inhibitor with an inhibitor of pd-l1, pd-1, or ctla-4 and uses and compositions thereof |
| EP3565837B1 (en) | 2017-01-05 | 2024-04-10 | Netris Pharma | Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs |
-
2018
- 2018-01-05 EP EP18701254.7A patent/EP3565837B1/en active Active
- 2018-01-05 EA EA201991302A patent/EA039433B1/ru unknown
- 2018-01-05 KR KR1020197019645A patent/KR102679324B1/ko active Active
- 2018-01-05 CN CN201880006141.0A patent/CN110291105B/zh active Active
- 2018-01-05 WO PCT/EP2018/050289 patent/WO2018127570A1/en not_active Ceased
- 2018-01-05 US US16/476,239 patent/US12162932B2/en active Active
- 2018-01-05 CA CA3048347A patent/CA3048347A1/en active Pending
- 2018-01-05 AU AU2018205730A patent/AU2018205730B2/en active Active
- 2018-01-05 IL IL267775A patent/IL267775B1/en unknown
- 2018-01-05 JP JP2019536507A patent/JP7211952B2/ja active Active
-
2022
- 2022-09-22 JP JP2022151769A patent/JP2022176250A/ja active Pending
-
2024
- 2024-09-16 US US18/886,180 patent/US20250002572A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jeong et al. | Novel anti-4-1BB× PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade | |
| JP7284557B2 (ja) | 医薬組成物 | |
| HRP20220629T1 (hr) | Anti-cd73 antitijela i njihove upotrebe | |
| JP2018501197A5 (cg-RX-API-DMAC7.html) | ||
| JP2018508483A5 (cg-RX-API-DMAC7.html) | ||
| JP2022505679A5 (cg-RX-API-DMAC7.html) | ||
| HRP20210876T1 (hr) | Anti-tmprss2 antitijela i fragmenti koji vezuju antigen | |
| JP2019524693A5 (cg-RX-API-DMAC7.html) | ||
| JP2017535257A5 (cg-RX-API-DMAC7.html) | ||
| EA202092460A1 (ru) | Антитела к ox40 и способы применения | |
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| RU2016114504A (ru) | Би- или полиспецифические полипептиды, связывающие поверхностные антигены иммунных эффекторных клеток и антигены hbv для лечения инфекций bv и ассоциированных с ними состояний | |
| JP2016536322A5 (cg-RX-API-DMAC7.html) | ||
| JP2018523493A5 (cg-RX-API-DMAC7.html) | ||
| JP2016539096A5 (cg-RX-API-DMAC7.html) | ||
| JP2016527286A5 (cg-RX-API-DMAC7.html) | ||
| RU2017105118A (ru) | Нейтрализация ингибирующих путей в лимфоцитах | |
| JP2019511212A5 (cg-RX-API-DMAC7.html) | ||
| RU2018106452A (ru) | Поливалетные и полиспецифичные gitr-связывающие слитые белки | |
| JP2018532383A5 (cg-RX-API-DMAC7.html) | ||
| HRP20201528T1 (hr) | Biparatopikalni polipeptidi koji antagoniziraju wnt signalizaciju u tumorskim stanicama | |
| MY188237A (en) | Anti-pd-l1 antibodies and uses thereof | |
| HRP20201785T1 (hr) | Multivalentni i multispecifični fuzijski proteini koji vežu dr5 | |
| RU2018125490A (ru) | Нейтрализация ингибиторных путей в лимфоцитах | |
| Häsler et al. | VNAR single-domain antibodies specific for BAFF inhibit B cell development by molecular mimicry |